A phase II trial of topotecan and gemcitabine in patients with previously treated, advanced non-small cell lung carcinoma

Cancer

Volumn 95, Issue 6, 2002, Pages 1274-1278

  Rinaldi, David A ^a   Lormand, Nancy A ^a   Brierre, Joseph E ^a   Cole, James L ^a   Barnes, Brian C ^a   Mills, Glen ^b   Yadlapati, Siva ^c   Fontenot, M Felicia ^a   Buller, Eric J ^a   Rainey, John M ^a  

^a Louisiana Oncology Associates   (United States)

^b LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c Medical Oncology   (United States)

Author keywords

Gemcitabine; Nonsmall cell lung carcinoma; Topotecan

Indexed keywords

ANTIEMETIC AGENT; FUROSEMIDE; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; HYCAMPTIN; TOPOTECAN;

ADULT; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; BLOOD TOXICITY; BODY WEIGHT DISORDER; BREATHING DISORDER; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; DERMATITIS; DIARRHEA; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SURVIVAL RATE; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; SURVIVAL RATE; TOPOTECAN;

EID: 0037105608     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.10806     Document Type: Article

References (20)

1. Phase II study of topotecan in metastatic non-small-cell lung cancer
2. Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy
3. A phase II study of oral topotecan in advanced non-small cell lung cancer: Useful symptom palliation and 10 month median survival
4. DNA topoisomerase inhibitors
5. Topoisomerase interactive agents
6. Investigational drugs
7. Antimetabolites
8. Efficacy of single-agent gemcitabine in advanced non-small-cell lung cancer: A review
9. Single agents in the second-line treatment of non-small cell lung cancer
10. Second-line chemotherapy in relapsing or refractory non-small cell lung cancer: A review
11. Combined therapy with topotecan and gemcitabine in patients with inoperable or metastatic non-small cell lung cancer
12. A phase I-II trial of topotecan and gemcitabine in patients with previously treated, advanced non-small cell lung cancer (LOA-3)
13. A phase II trial testing gemcitabine as second-line chemotherapy for non-small cell lung cancer
14. Gemcitabine as second-line treatment for advanced non-small cell lung cancer: A phase II trial
15. Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small cell lung cancer
16. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens
17. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy
18. Docetaxel and granulocyte colony-stimulating factor in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy: A multicenter phase II trial
19. Activity of docetaxel in platinum-treated non-small cell lung cancer: Results of a phase II multicenter Trial